BRPI0912536A2 - método para produzir um carregador particulado, carreador particulado, composição farmacêutica, e, e uso da mesma. - Google Patents

método para produzir um carregador particulado, carreador particulado, composição farmacêutica, e, e uso da mesma.

Info

Publication number
BRPI0912536A2
BRPI0912536A2 BRPI0912536A BRPI0912536A BRPI0912536A2 BR PI0912536 A2 BRPI0912536 A2 BR PI0912536A2 BR PI0912536 A BRPI0912536 A BR PI0912536A BR PI0912536 A BRPI0912536 A BR PI0912536A BR PI0912536 A2 BRPI0912536 A2 BR PI0912536A2
Authority
BR
Brazil
Prior art keywords
particulate carrier
producing
pharmaceutical composition
particulate
carrier
Prior art date
Application number
BRPI0912536A
Other languages
English (en)
Portuguese (pt)
Inventor
Papanicolaou Irene
Fidanboylu Mehmet
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0912536A2 publication Critical patent/BRPI0912536A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BRPI0912536A 2008-05-06 2009-05-05 método para produzir um carregador particulado, carreador particulado, composição farmacêutica, e, e uso da mesma. BRPI0912536A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5077508P 2008-05-06 2008-05-06
US7417108P 2008-06-20 2008-06-20
PCT/EP2009/055437 WO2009135854A2 (en) 2008-05-06 2009-05-05 Encapsulation of biologically active agents

Publications (1)

Publication Number Publication Date
BRPI0912536A2 true BRPI0912536A2 (pt) 2018-10-16

Family

ID=43125568

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912536A BRPI0912536A2 (pt) 2008-05-06 2009-05-05 método para produzir um carregador particulado, carreador particulado, composição farmacêutica, e, e uso da mesma.

Country Status (11)

Country Link
US (1) US20110059167A1 (enExample)
EP (1) EP2271324A2 (enExample)
JP (1) JP2011519893A (enExample)
CN (1) CN102083423A (enExample)
AU (1) AU2009245785A1 (enExample)
BR (1) BRPI0912536A2 (enExample)
EA (1) EA201001567A1 (enExample)
IL (1) IL208666A0 (enExample)
MX (1) MX2010012141A (enExample)
WO (1) WO2009135854A2 (enExample)
ZA (1) ZA201007437B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102088963A (zh) * 2008-05-06 2011-06-08 葛兰素集团有限公司 生物活性剂的囊封方法
DK3003343T3 (da) 2013-06-07 2020-02-03 Univ Johns Hopkins Biomimetisk peptid og bionedbrydelig leveringsplatform til behandling af angiogenese- og lymfangiogeneseafhængige sygdomme
US20190254983A1 (en) * 2015-11-20 2019-08-22 AbbVie Deutschland GmbH & Co. KG Surface-modified nanospheres encapsulating antigen-binding molecules
US11491114B2 (en) * 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0683667A1 (en) * 1993-02-15 1995-11-29 Shield Research Limited Polyalkylcyanoacrylate nanocapsules
DE59409568D1 (de) * 1993-09-09 2000-11-30 Schering Ag Wirkstoffe und gas enthaltende mikropartikel
EP0975334B1 (en) * 1997-04-17 2003-10-22 Amgen Inc., Biodegradable microparticles for the sustained delivery of therapeutic drugs
US20030152636A1 (en) * 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
US7332159B2 (en) * 2004-09-30 2008-02-19 Board Of Regents Of The University Of Nebraska Method and composition for inhibiting reperfusion injury in the brain
US7597907B2 (en) * 2004-11-05 2009-10-06 Trustees Of The University Of Pennsylvania Antioxidant polymer nanocarriers for use in preventing oxidative injury

Also Published As

Publication number Publication date
WO2009135854A2 (en) 2009-11-12
EA201001567A1 (ru) 2011-08-30
IL208666A0 (en) 2010-12-30
CN102083423A (zh) 2011-06-01
EP2271324A2 (en) 2011-01-12
US20110059167A1 (en) 2011-03-10
WO2009135854A3 (en) 2010-11-04
JP2011519893A (ja) 2011-07-14
ZA201007437B (en) 2012-03-28
AU2009245785A1 (en) 2009-11-12
MX2010012141A (es) 2010-12-17

Similar Documents

Publication Publication Date Title
BRPI0909691A2 (pt) Composto, método para preparar um composto, e, composição farmacêutica
BRPI0818483A2 (pt) Método para preparar uma composição farmacêutica, composição farmacêutica, e, uso da mesma.
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI1014700A2 (pt) composição de revestimento e método para a fabricação e uso da mesma.
BRPI0914918A2 (pt) forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida.
BRPI0816331A2 (pt) Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.
BRPI0810370A2 (pt) Stent revestido, e, método para preparar um stent
BRPI0821676A2 (pt) Composto, composição farmacêutica, e, processo para a preparação dos compostos.
BRPI0910734A2 (pt) composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo.
BRPI0814777A2 (pt) Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica.
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0916689A2 (pt) composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida.
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BRPI0814688A2 (pt) composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar doenças, e, composição farmacêutica
BRPI0611956A2 (pt) composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
DK2051975T3 (da) Substituerede prolinamider, fremstilling deraf og anvendelse deraf som lægemiddel.
BRPI0911554A2 (pt) Microemulsão, processo para a preparação de uma microemulsão, e, uso da microemulsão.
BRPI0909198A2 (pt) composto antifolato, composto, método para preparar um composto antifolato, composição farmacêutica, método para tratar
BRPI0911944A2 (pt) método para preparar um catalisador componente, sistema catalítico e catalisador componente
BRPI0903914A2 (pt) Uso de um composto, método para analisar a eficácia de uma composição de liberação prolongada, e, composição farmacêutica.
BRPI0807001A2 (pt) Formulação farmacêutica, e, método para preparação de uma formulação farmacêutica.

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]